Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 – Clinical Trial Not Allowed)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 16, 2026
Can you apply?
This grant is for translating research into clinical diagnostic and treatment technologies through academic-industry partnerships.
Eligible applicants include universities, medical schools, research institutions, and small businesses with NIH funding capability. Projects must demonstrate collaborative partnerships between academic researchers and industry partners. Research must focus on translating laboratory discoveries into practical diagnostic or therapeutic tools.
Geographic scope is U.S.-based institutions with appropriate research infrastructure. Activities funded include technology development, proof-of-concept studies, and preclinical validation. Clinical trials are explicitly not allowed under this mechanism.
Not the right fit? Find grants for your organization in 5 questions →
Program description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.
Who can apply
Eligible applicants
How to apply
Application links
Required documents
- SF-424 (R&R)
- Project Narrative
- Budget and Budget Justification
- Biographical Sketches (key personnel)
- Letters of Support (from industry partner and institutional leadership)
- Resource Sharing Plans (if applicable)
- Data Management Plan
- NIH Conflict of Interest Form
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.395 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$353,109,533
-
$226,323,195
-
$180,463,644
-
$148,820,579
-
$143,093,026
-
$125,672,442
-
$124,513,663
-
$112,462,142
-
$109,067,856
-
$104,790,648
Top States by Funding
- CA 10 awards $871.7M
- PA 5 awards $513.3M
- NY 7 awards $462.6M
- MA 7 awards $282.7M
- IL 3 awards $274.4M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.395). How funding has trended year over year.
| 2024 | $1,298,551,504 | |
| 2025 | $1,414,965,434 | |
| 2026 est. | $926,626,977 |
FAQ
Who can apply for this grant?
Universities, medical schools, research institutions, and eligible small businesses can apply. You must have an academic-industry partnership. Industry partners do not need to be prime applicants.
What types of projects are funded?
Technology translation from lab to clinical application is supported. Proof-of-concept studies and preclinical validation are eligible. Clinical trials and human studies are not permitted.
What is the typical funding range?
R01 grants typically fund $250,000–$500,000+ per year for 3–5 years. Exact amounts vary by review panel and scientific merit scores.
How competitive is this mechanism?
NIH R01 grants are highly competitive with success rates often 15–25%. Strong preliminary data and a credible partnership are essential.
When is the deadline?
The deadline is January 7, 2028. Applications typically require 2–3 months of preparation for a strong submission.
💡 Tips for applicants
- Start with strong preliminary data showing the diagnostic or treatment concept works at the bench level.
- Clearly document the partnership roles: which partner leads which activities and contributes what resources.
- Include a commercialization or implementation pathway showing how the technology will reach patients.
- Address intellectual property (IP) ownership and licensing upfront; reviewers want clarity on IP agreements.
- Budget realistically for both academic institution and industry partner costs; justify industry contributions clearly.
⚠️ Common mistakes
Weak or insufficient preliminary data suggesting the technology is still too early-stage. Vague partnership descriptions without clear roles, resource commitments, or IP agreements. Proposing clinical trials or human subject research, which violates grant restrictions.
Similar grants
- OPEN Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 – Clinical Trial Optional) — National Institutes of Health
- OPEN Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) — National Institutes of Health
- OPEN Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) — National Institutes of Health